Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Hepatology

Volumn 59, Issue 1, 2014, Pages 121-129

  Verrijken, An ^a   Francque, Sven ^a   Mertens, Ilse ^a   Prawitt, Janne ^b   Caron, Sandrine ^b   Hubens, Guy ^a   Van Marck, Eric ^a   Staels, Bart ^b   Michielsen, Peter ^a   Van Gaal, Luc ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR; SERPINE1 PROTEIN, HUMAN;

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER LOBE; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; WAIST CIRCUMFERENCE; ANTHROPOMETRY; BLOOD; BLOOD CLOTTING; FATTY LIVER; GENE EXPRESSION; LIVER; LIVER FUNCTION TEST; METABOLIC SYNDROME X; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; COMPLICATION;

ADULT; ANTHROPOMETRY; BLOOD COAGULATION; FATTY LIVER; FEMALE; GENE EXPRESSION; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; THROMBOSIS;

EID: 84894746098     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26510     Document Type: Article

References (39)

1. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010;5:145-171.
2. Verrijken A, Francque S, Van Gaal L. The metabolic syndrome and the liver. Acta Gastroenterol Belg 2008;71:48-59.
3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-1350.
4. Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis 2012;220:287-293.
5. Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin Liver Dis 2012;32:39-48.
6. Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol 2012;57:203-212.
7. Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011;54:1071-1081.
8. Villa E, Zecchini R, Marietta M, Bernabucci V, Lei B, Vukotic R, et al. Enoxaparin prevents portal vein thrombosis (PVT) and decompensation in advanced cirrhotic patients: final report of a prospective randomized controlled study. Hepatology 2011;54:article 418a.
9. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men-role of the metabolic syndrome. Thromb Haemost 1996;76:69-73.
10. Bastard JP, Bruckert E, Porquet D, Jardel C, Ankri A, Delattre J, Hainque B. Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase. Thromb Res 1996;81:271-275.
11. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008;16:1394-1399.
12. Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003;23:688-694.
13. Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 2011;31:176-183.
14. Targher G, Bertolini L, Scala L, Zenari L, Lippi G, Franchini M, Arcaro G. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007;30:e31-e32.
15. de Larranaga G, Wingeyer SP, Graffigna M, Belli S, Bendezu K, Alvarez S, et al. Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clin Appl Thromb Hemost 2008;14:319-324.
16. Sookoian S, Castano GO, Burgueno AL, Rosselli MS, Gianotti TF, Mallardi P, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-591.
17. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009;13:533-544.
18. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-15.
19. Merkel C, Bolognesi M, Bellon S, Bianco S, Honisch B, Lampe H, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992;33:836-842.
20. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
21. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810-820.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
25. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059-1062.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
27. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
28. Schouten JN, Francque S, Van Vlierberghe H, Colle I, Nevens F, Delwaide J, et al. The influence of laboratory-induced MELD score differences on liver allocation: more reality than myth. Clin Transplant 2012;26:E62-E70.
29. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005;11:5834-5839.
30. Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, et al. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol 2009;51:931-938.
31. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med 2005;22:1354-1358.
32. Espino A, Villagran A, Vollrath V, Hanckes P, Salas R, Farah A, et al. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease. Ann Hepatol 2011;10:493-501.
33. Barbato A, Iacone R, Tarantino G, Russo O, Sorrentino P, Avallone S, et al. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med 2009;4:315-323.
34. Bruckert E, Ankri A, Giral P, Turpin G. Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patients. Thromb Haemost 1994;72:434-437.
35. Dimova EY, Kietzmann T. Metabolic, hormonal, and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008;100:992-1006.
36. Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol 2012;227:493-507.
37. Mertens I, Van Gaal LF. Obesity, haemostasis, and the fibrinolytic system. Obes Rev 2002;3:85-101.
38. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.
39. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.